phrykt

Heartflow, Inc. (HTFL): who owns it and who trades it

As of Nov 16, 2026, HTFL insiders reported 40 open-market sales worth $144M and 1 purchase worth $1.1M in the last 12 months, with 20% of the sale value made under pre-set 10b5-1 plans. The largest seller was Bain Capital Life Sciences III General Partner, LLC (10% owner), with $58.9M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Heartflow

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns HTFL

194 funds and institutions reported HTFL shares worth $2.2B at the end of Q2 2026, about 89% of the company. The largest holder is Bain Capital Life Sciences Investors, LLC with 9.8%.

Funds and institutions (13F) 89%Everyone else 11%

10 largest owners, by share of the company

Bain Capital Life Sciences Investors, LLC9.8%
Wellington Management Group LLP9.1%
BlackRock, Inc.6.0%
FMR LLC (Fidelity)5.6%
Vanguard Portfolio Management LLC4.2%
Bamco Inc3.7%
Vanguard Capital Management LLC3.2%
Jupiter Topco LLC2.8%
Invesco Ltd.2.7%
Alliancebernstein L.P.2.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Bain Capital Life Sciences Investors, LLC8.45M9.80%$248M-19%
Wellington Management Group LLP7.86M9.12%$231M-34%
BlackRock, Inc.5.20M6.03%$153M+255%
FMR LLC (Fidelity)4.82M5.59%$141M-11%
Vanguard Portfolio Management LLC3.58M4.16%$105M+75%
Bamco Inc3.23M3.74%$94.6M-16%
Vanguard Capital Management LLC2.75M3.19%$80.8M+45%
Jupiter Topco LLC2.42M2.81%$71M–
Invesco Ltd.2.30M2.67%$67.4M+20%
Alliancebernstein L.P.1.92M2.23%$46.8M+57%
Point72 Asset Management, L.P.1.72M2.00%$50.5M+220%
Summit Partners Public Asset Management, LLC1.69M1.97%$49.7M+90%
State Street Corp1.47M1.70%$43.3M+225%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC1.47M1.70%$43M+4%
Geode Capital Management, LLC1.36M1.58%$39.9M+151%
Nuveen, LLC1.35M1.57%$39.7M+5723%
California State Teachers Retirement System1.29M1.50%$44M+4293%
Morgan Stanley1.05M1.22%$31M+24%
UBS Group AG975,5101.13%$28.6M+127%
BNP PARIBAS ASSET MANAGEMENT Holding S.A.931,1601.08%$27.3M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, HTFL insiders reported $1.1M of open-market purchases and $144M of sales. 20% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$1.1M
1 trades, 1 people
Sales, 12 months
$144M
40 trades, 6 people
Sales under a 10b5-1 plan
20%
Share of sale value
Latest trade
Nov 10, 2026
Filed Nov 10, 2026

Purchases and sales by month

$61.1M$61.1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 10, 2026John C.M. FarquharCEOSale plan38,900$55.74$2.2MForm 4
Nov 9, 2026Vikram VergheseCFOSale plan3,587$53.15$191KForm 4
Oct 22, 2026Campbell RogersChief Medical OfficerSale plan23,933$55.01$1.3MForm 4
Oct 12, 2026John C.M. FarquharCEOSale plan38,900$49.57$1.9MForm 4
Sep 18, 2026Campbell RogersChief Medical OfficerSale plan19,682$50.15$987KForm 4
Sep 18, 2026Vikram VergheseCFOSale plan16,766$50.75$851KForm 4
Sep 17, 2026Vikram VergheseCFOSale plan7,579$50.11$380KForm 4
Sep 15, 2026Vikram VergheseCFOSale plan668$50.01$33.4KForm 4
Sep 14, 2026Vikram VergheseCFOSale plan4,593$50.24$231KForm 4
Sep 11, 2026Vikram VergheseCFOSale plan29,714$50.06$1.5MForm 4
Sep 11, 2026John C.M. FarquharCEOSale plan3,890$50.00$194KForm 4
Sep 10, 2026John C.M. FarquharCEOSale plan35,010$46.42$1.6MForm 4
Sep 8, 2026Vikram VergheseCFOSale plan6,640$50.03$332KForm 4
Sep 3, 2026Vikram VergheseCFOSale plan27,540$49.69$1.4MForm 4
Sep 2, 2026Vikram VergheseCFOSale plan5,876$50.60$297KForm 4
Aug 21, 2026John C.M. FarquharCEOSale plan27,230$50.00$1.4MForm 4
Aug 18, 2026John C.M. FarquharCEOSale plan32,676$45.00$1.5MForm 4
Aug 17, 2026Campbell RogersChief Medical OfficerSale plan9,219$41.23$380KForm 4
Aug 14, 2026John C.M. FarquharCEOSale plan15,560$39.06$608KForm 4
Aug 10, 2026John C.M. FarquharCEOSale plan22,562$28.31$639KForm 4
Jul 15, 2026Campbell RogersChief Medical OfficerSale plan9,219$25.72$237KForm 4
Jul 10, 2026John C.M. FarquharCEOSale plan22,562$27.75$626KForm 4
Jun 24, 2026John C.M. FarquharCEOSale plan38,900$35.00$1.4MForm 4
Jun 10, 2026John C.M. FarquharCEOSale plan22,562$28.50$643KForm 4
May 18, 2026Campbell RogersChief Medical OfficerSale plan9,219$28.34$261KForm 4
May 11, 2026John C.M. FarquharCEOSale plan22,562$29.12$657KForm 4
Apr 30, 2026Bain Capital Life Sciences III General Partner, LLC +410% ownerSale892,533$29.18$26MForm 4
Apr 30, 2026Bain Capital Life Sciences III General Partner, LLC +410% ownerSale56,224$30.05$1.7MForm 4
Apr 29, 2026Bain Capital Life Sciences III General Partner, LLC +410% ownerSale797,133$29.37$23.4MForm 4
Apr 28, 2026Bain Capital Life Sciences III General Partner, LLC +410% ownerSale254,110$30.51$7.8MForm 4
Apr 10, 2026John C.M. FarquharCEOSale plan22,562$26.72$603KForm 4
Apr 1, 2026Campbell RogersChief Medical OfficerSale plan64,533$24.64$1.6MForm 4
Mar 19, 2026Campbell RogersChief Medical OfficerSale plan64,533$25.69$1.7MForm 4
Mar 18, 2026John C.M. FarquharCEOSale plan9,725$25.00$243KForm 4
Mar 10, 2026John C.M. FarquharCEOSale plan12,837$22.66$291KForm 4
Mar 5, 2026Julie A CullivanDirectorSale plan9,122$25.00$228KForm 4
Feb 12, 2026Campbell RogersChief Medical OfficerSale plan65,153$24.49$1.6MForm 4
Feb 10, 2026John C.M. FarquharCEOSale plan22,562$27.46$620KForm 4
Feb 5, 2026Julie A CullivanDirectorSale plan8,000$27.32$219KForm 4
Feb 4, 2026Bain Capital Life Sciences Investors, LLC +410% ownerSale2.00M$28.05$56.1MForm 4
Dec 16, 2025Jeffrey C LightcapDirectorPurchase40,000$26.34$1.1MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Bain Capital Life Sciences III General Partner, LLC10% owner–$58.9MApr 30, 2026
Bain Capital Life Sciences Investors, LLC10% owner–$56.1MFeb 4, 2026
John C.M. FarquharChief Executive Officer, Director–$15MNov 10, 2026
Campbell RogersChief Medical Officer–$8MOct 22, 2026
Vikram VergheseChief Financial Officer–$5.2MNov 9, 2026
Jeffrey C LightcapDirector$1.1M–Dec 16, 2025
Julie A CullivanDirector–$447KMar 5, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

HTFL short interest

Moderate short interest. 6.5% of HTFL shares are sold short: about 1 share in 15. Over the last 12 reports the number of shares short went up 64%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.69M HTFL shares were sold short, 6.5% of the shares outstanding, down 22.4% from the report before. At the average daily volume of 1.62M shares, buying them all back would take about 3.5 trading days (days to cover).

Shares short, % of all shares

6.54%May 15Oct 309.09%

Days to cover

3.5May 15Oct 307.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.69M6.54%-22%1.62M3.5
Oct 15, 20267.33M8.43%+8%1.66M4.4
Sep 30, 20266.81M7.84%+21%2.04M3.3
Sep 15, 20265.63M6.47%-7%1.84M3.1
Aug 31, 20266.07M6.98%-10%2.39M2.5
Aug 14, 20266.78M7.80%-1%1.76M3.9
Jul 31, 20266.85M7.88%+17%1.04M6.6
Jul 15, 20265.87M6.81%+13%1.42M4.2
Jun 30, 20265.18M6.00%+23%2.98M1.7
Jun 15, 20264.21M4.89%+16%1.15M3.7
May 29, 20263.64M4.22%+5%1.25M2.9
May 15, 20263.48M4.03%-20%1.05M3.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Heartflow company events

Heartflow filed 5 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Aug 13, 2026.

  1. Aug 13, 2026ResultsReleased financial results. Filing
  2. Jun 18, 2026VoteReported shareholder vote results. Filing
  3. May 14, 2026ResultsReleased financial results. Filing
  4. Mar 18, 2026ResultsReleased financial results. Filing
  5. Jan 12, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Heartflow financials

Famous investors that hold HTFL

4 of the 50 well-known investors we track reported holding HTFL in their latest 13F filing. The largest position is Jim Simons's, worth $49.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026993,900$49.4M0.1%+160%
Israel Englander · Millennium ManagementQ3 2026933,918$46.5M0.0%+1%
Steve Cohen · Point72 Asset ManagementQ3 2026681,657$33.9M0.1%-60%
Ken Griffin · Citadel AdvisorsQ3 2026287,310$14.3M0.0%-64%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named HTFL in the last 120 days.

FiledHolderFormStake
Nov 16, 2026BCLS Fund III Investments, LP13G/A5.1%
Nov 16, 2026Wellington Management Group LLP13G/A6.4%
Nov 16, 2026BCLS Fund III Investments, LP13G/A5.1%
Nov 16, 2026Wellington Management Group LLP13G/A6.4%

Questions about Heartflow, Inc. (HTFL) stock

Who owns the most HTFL stock?

The largest reported owner of Heartflow, Inc. (HTFL) is Bain Capital Life Sciences Investors, LLC, with 9.8% of the company. In total, 194 funds and institutions reported holding HTFL at the end of Q2 2026, together about 89% of the shares. See the largest owners.

Are HTFL insiders buying or selling?

In the last 12 months, HTFL insiders reported 1 open-market purchase worth $1.1M and 40 sales worth $144M. The latest trade was on Nov 10, 2026. See every trade.

What is the short interest in HTFL?

As of Oct 30, 2026, 5.69M HTFL shares were sold short, 6.5% of the shares outstanding, down 22.4% from the report before. At the average daily volume of 1.62M shares, buying them all back would take about 3.5 trading days (days to cover). See the history.

Which famous investors hold HTFL?

4 of the 50 well-known investors we track reported HTFL in their latest 13F filing, including Jim Simons, Israel Englander, Steve Cohen. The largest position is worth $49.4M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.